124 related articles for article (PubMed ID: 15690710)
21. Coexistence of polycystic ovary syndrome and pelvic endometriosis.
Singh KB; Patel YC; Wortsman J
Obstet Gynecol; 1989 Oct; 74(4):650-2. PubMed ID: 2797642
[TBL] [Abstract][Full Text] [Related]
22. Neuropeptide Y, leptin, galanin and insulin in women with polycystic ovary syndrome.
Baranowska B; Radzikowska M; Wasilewska-Dziubińska E; Kapliński A; Roguski K; Płonowski A
Gynecol Endocrinol; 1999 Oct; 13(5):344-51. PubMed ID: 10599552
[TBL] [Abstract][Full Text] [Related]
23. Inappropriate gonadotropin secretion in polycystic ovary syndrome.
Hsu MI; Liou TH; Liang SJ; Su HW; Wu CH; Hsu CS
Fertil Steril; 2009 Apr; 91(4):1168-74. PubMed ID: 18325508
[TBL] [Abstract][Full Text] [Related]
24. Plasma adiponectin and insulin resistance in women with polycystic ovary syndrome.
Ardawi MS; Rouzi AA
Fertil Steril; 2005 Jun; 83(6):1708-16. PubMed ID: 15950640
[TBL] [Abstract][Full Text] [Related]
25. [Interrelationship of abnormal family history in the first degree relatives and clinical phenotype of patients with polycystic ovary syndrome].
Wang Y; Mao WW; Chen YJ; Li MZ; Qiao J; Wang LN
Zhonghua Fu Chan Ke Za Zhi; 2007 Nov; 42(11):756-60. PubMed ID: 18307903
[TBL] [Abstract][Full Text] [Related]
26. Effect of obesity on the clinical and hormonal characteristics of the polycystic ovary syndrome.
Singh KB; Mahajan DK; Wortsman J
J Reprod Med; 1994 Oct; 39(10):805-8. PubMed ID: 7837128
[TBL] [Abstract][Full Text] [Related]
27. Clinical and metabolic characteristics of polycystic ovary syndrome without polycystic ovary: a pilot study on Chinese women.
Shi Y; Gao X; Sun X; Zhang P; Chen Z
Fertil Steril; 2008 Oct; 90(4):1139-43. PubMed ID: 17889857
[TBL] [Abstract][Full Text] [Related]
28. Ovulatory disorders in women with polycystic ovary syndrome.
Franks S; Adams J; Mason H; Polson D
Clin Obstet Gynaecol; 1985 Sep; 12(3):605-32. PubMed ID: 3933879
[TBL] [Abstract][Full Text] [Related]
29. Fasting glucose/insulin ratio. An index to differentiate normo from hyperinsulinemic women with polycystic ovary syndrome.
Parra A; Ramírez A; Espinosa de los Monteros A
Rev Invest Clin; 1994; 46(5):363-8. PubMed ID: 7839016
[TBL] [Abstract][Full Text] [Related]
30. [Different types of menstrual cycle and their significance in Chinese women diagnosed with polycystic ovary syndrome according to the Rotterdam consensus criteria].
Xu XH; Tan YC; Shi YH; Wang B; Ju XQ; Zheng QM; Hao CF; Chen ZJ
Zhonghua Yi Xue Za Zhi; 2009 Oct; 89(37):2604-6. PubMed ID: 20137675
[TBL] [Abstract][Full Text] [Related]
31. Effects of metformin on clinical and biochemical parameters in polycystic ovary syndrome.
Kriplani A; Agarwal N
J Reprod Med; 2004 May; 49(5):361-7. PubMed ID: 15214709
[TBL] [Abstract][Full Text] [Related]
32. [Exploration of the classification of polycystic ovarian syndrome].
Lin JF; Li X; Zhu MW
Zhonghua Fu Chan Ke Za Zhi; 2006 Oct; 41(10):684-8. PubMed ID: 17199924
[TBL] [Abstract][Full Text] [Related]
33. [Is the assessment of biological activity of prolactin essential in the diagnosis of hyperprolactinemia?].
Kostrzak A; Warenik-Szymankiewicz A; Meczekalski B
Pol Merkur Lekarski; 2010 May; 28(167):359-61. PubMed ID: 20568397
[TBL] [Abstract][Full Text] [Related]
34. The role of plasma renin activity in distinguishing patients with polycystic ovary syndrome (PCOS) from oligomenorrheic patients without PCOS.
Uncu G; Sözer MC; Develioğlu O; Cengiz C
Gynecol Endocrinol; 2002 Dec; 16(6):447-52. PubMed ID: 12626031
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome.
Zacchè MM; Caputo L; Filippis S; Zacchè G; Dindelli M; Ferrari A
Gynecol Endocrinol; 2009 Aug; 25(8):508-13. PubMed ID: 19551544
[TBL] [Abstract][Full Text] [Related]
36. A simple screening approach for assessing community prevalence and phenotype of polycystic ovary syndrome in a semi-urban population in Sri Lanka.
Kumarapeli V; Seneviratne Rde A; Wijeyaratne CN; Yapa RM; Dodampahala SH
Am J Epidemiol; 2008 Aug; 168(3):321-8. PubMed ID: 18550559
[TBL] [Abstract][Full Text] [Related]
37. Clinical and biochemical presentations of polycystic ovary syndrome among obese and nonobese women.
Liou TH; Yang JH; Hsieh CH; Lee CY; Hsu CS; Hsu MI
Fertil Steril; 2009 Dec; 92(6):1960-5. PubMed ID: 18980763
[TBL] [Abstract][Full Text] [Related]
38. Galactorrhea and hyperprolactinemia during treatment of polycystic ovary syndrome.
Wortsman J; Hirschowitz JS
Obstet Gynecol; 1980 Apr; 55(4):460-3. PubMed ID: 6768040
[TBL] [Abstract][Full Text] [Related]
39. Prolactin response to clomiphene citrate is different in hyperprolactinemic polycystic ovary syndrome and idiopathic hyperprolactinemia.
Lewinthal D; Corenblum B; Taylor PJ
Int J Fertil; 1987; 32(3):185-7, 191. PubMed ID: 2885281
[No Abstract] [Full Text] [Related]
40. Endocrinological and clinical analysis of hyperprolactinemic patients with and without ultrasonically diagnosed polycystic ovarian changes.
Işik AZ; Gülekli B; Zorlu CG; Ergin T; Gökmen O
Gynecol Obstet Invest; 1997; 43(3):183-5. PubMed ID: 9127132
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
